Urinary Bladder Cancer
Conditions
Brief summary
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)
Interventions
TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
Sponsors
Taris Biomedical LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A documented history of histologically-confirmed low or intermediate risk urothelial carcinoma of the bladder, excluding carcinoma in situ (pTis), pathologic stage pT1 (invasive into lamina propria) and high-Grade disease, judged not to be muscle infiltrating (pT2 or greater) and accessible for resection. * Adequate laboratory parameters. * Screening urinalysis showing no clinically significant abnormalities except those attributable to bladder cancer. * Not undergoing active treatment in last 3 months for prior or concurrent neoplastic disease and have fully recovered from treatment effects. Patients undergoing concurrent hormonal therapy treatment for prostate cancer will be allowed to enroll.
Exclusion criteria
* Exposure to BCG therapy and/or any other intravesical. chemotherapeutic agent less than 1 year prior to enrollment, except single postoperative instillations. * Absence of visible tumor at Screening. * Any previous exposure to intravesical gemcitabine instillations within the past 12 months. * Presence of any bladder or urethral anatomical feature that in the opinion of the investigator may prevent the safe placement, indwelling use or removal of TAR-200 (i.e. bladder diverticula, complete incontinence). * Patients with a high-Grade urine cytology at recurrence. * Currently receiving other systemic or intravesical chemotherapy. * Pelvic radiotherapy administered within 6 months prior to enrollment. Patients who received radiotherapy ≥ 6 months prior to enrollment must demonstrate no cystoscopic evidence or clinical symptoms of radiation cystitis. * Bladder Post-Void Residual Volume (PVR) of \> 250-mL. * Active, uncontrolled urogenital bacterial, viral, or fungal infections, including urinary tract infection. Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study. * History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation. * Concomitant immunosuppressive medications, such as methotrexate or TNF inhibitors, within 2 weeks of Study Day 0, exclusive of steroid doses ≤5 mg daily. * Female subject who is pregnant (as verified by urine test at time of screening) or lactating, or of childbearing potential and not using acceptable methods of contraception. * Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up. * Other unspecified reasons that, in the opinion of the investigator or TARIS, make the patient unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety as defined by the number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0 | From the point of signing the informed consent form through last study visit, up to 59 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants who are tolerant of TAR-200 indwelling (Arm 1) | From Day 0 up to Day 7 | — |
| Cmax, plasma dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in plasma. |
| Tmax, plasma dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in plasma. |
| Cavg, plasma dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in plasma. |
| Cmax, plasma dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma. |
| Tmax, plasma dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma |
| Cavg, plasma dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma. |
| Cmax, urine dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine. |
| Tmax, urine dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in urine |
| Cavg, urine dFdU (Arm 1) | From Day 0 up to Day 32 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in urine. |
| Cmax, urine dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine. |
| Tmax, urine dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine. |
| Cavg, urine dFdC (Arm 1) | From Day 0 up to Day 32 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine |
| Preliminary anti-tumor effects will be assessed in tumor material (post-treatment) for assessment of immunohistochemical tissue biomarkers of drug-induced cell death (AKT, CD31, Ki67, TUNEL). (Arm 1) | Anti-tumor analysis will occur at the following study day visit Day 28 | — |
| Number of participants who are tolerant of TAR-200 indwelling (Arm 1) | From Day 0 up to Day 7 | — |
| Percentage of participants who are tolerant of TAR-200 indwelling (Arm 2) | From Day 0 up to Day 21 | — |
| Cmax, plasma dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in plasma. |
| Tmax, plasma dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in plasma. |
| Cavg, plasma dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in plasma. |
| Cmax, plasma dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma. |
| Tmax, plasma dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma |
| Cavg, plasma dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma. |
| Cmax, urine dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine. |
| Tmax, urine dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in urine |
| Cavg, urine dFdU (Arm 2) | From Day 0 up to Day 47 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in urine. |
| Cmax, urine dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine. |
| Tmax, urine dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine. |
| Cavg, urine dFdC (Arm 2) | From Day 0 up to Day 47 | Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine |
| Preliminary anti-tumor effects will be assessed in tumor material (post-treatment) for assessment of immunohistochemical tissue biomarkers of drug-induced cell death (AKT, CD31, Ki67, TUNEL). (Arm 2) | Anti-tumor analysis will occur at the following study day visit Day 42 | — |
| Number of participants who are tolerant of TAR-200 indwelling (Arm 2) | From Day 0 up to Day 21 | — |
Countries
Netherlands
Outcome results
None listed